Opinion on Rheumatology in France

Published within

« | 1 | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor
23 Apr 2001
CommentWire
CommentWire

NicOx/AstraZeneca: NO-Naproxen announcement stuns partner

Hopes for the leading compound in the CINOD class of arthritis drugs have been dealt a serious blow after it failed to live up to expectations in phase II trials. AstraZeneca may now pull out of its partnership with the drug's developer, NicOx. Although great things had been anticipated for the drug, it now seems highly unlikely that it will challenge the leading COX-II inhibitors.

Published By Datamonitor
28 Feb 2003
CommentWire
CommentWire

NicOx: FDA approval a step closer for naproxcinod, but marketing partner remains elusive

NicOx has filed a New Drug Application for osteoarthritis treatment naproxcinod to the FDA. While Datamonitor expects a positive decision, the success of the drug will hinge on NicOx obtaining a marketing partner, as the company currently has inadequate resources to commercialize naproxcinod on its own in the competitive and highly genericized US osteoarthritis market.

Published By Datamonitor
28 Sep 2009
ResearchWire
ResearchWire

Rheumatoid arthritis: growing fastest in France

Published By Datamonitor
14 May 2002
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001

« | 1 | » »|

No help is available.